Related references
Note: Only part of the references are listed.Effects of Atypical Protein Kinase C Inhibitor (DNDA) on Lung Cancer Proliferation and Migration by PKC-ι/FAK Ubiquitination Through the Cbl-b Pathway
Raja Reddy BommaReddy et al.
ONCOTARGETS AND THERAPY (2020)
PKC and PKN in heart disease
Valeria Marrocco et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Protein kinase C-iota-mediated glycolysis promotes non-small-cell lung cancer progression
Liu Liu et al.
ONCOTARGETS AND THERAPY (2019)
Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma
Kyung-Hee Kim et al.
BMC CANCER (2019)
Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma
Ning Yin et al.
CANCER CELL (2019)
PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation
Mohamed F. Salama et al.
ONCOGENE (2019)
HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma
Honghong Jiang et al.
ONCOLOGY LETTERS (2019)
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
Masaoki Ito et al.
CELL COMMUNICATION AND SIGNALING (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Protein kinase C: perfectly balanced
Alexandra C. Newton
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)
Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Noah Isakov
SEMINARS IN CANCER BIOLOGY (2018)
Protein kinase C as a tumor suppressor
Alexandra C. Newton
SEMINARS IN CANCER BIOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
Pei-Chih Lee et al.
CANCER CELL (2018)
Protein kinase C and cardiac dysfunction: a review
Raphael M. Singh et al.
HEART FAILURE REVIEWS (2017)
Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor
Alexandra C. Newton et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
M. G. Kris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma
Syed A. Ali et al.
CANCER CELL (2016)
Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease
Stephanie I. Alfonso et al.
SCIENCE SIGNALING (2016)
Classification and Pathology of Lung Cancer
Min Zheng
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2016)
Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease
Stephanie I. Alfonso et al.
SCIENCE SIGNALING (2016)
Cancer-Associated Protein Kinase C Mutations Reveal Kinase's Role as Tumor Suppressor
Corina E. Antal et al.
CELL (2015)
PKC-theta in regulatory and effector T-cell functions
Vedran Brezar et al.
FRONTIERS IN IMMUNOLOGY (2015)
The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials
L. L. Zhang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
Protein Kinase Cα Mediates Erlotinib Resistance in Lung Cancer Cells
Mahlet B. Abera et al.
MOLECULAR PHARMACOLOGY (2015)
PKCη is an anti-apoptotic kinase that predicts poor prognosis in breast and lung cancer
Udi Zurgil et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
The oncogenic role of PKCiota gene amplification and overexpression in Chinese non-small cell lung cancer
Qingquan Luo et al.
LUNG CANCER (2014)
PKC signaling in glioblastoma
Analia do Carmo et al.
CANCER BIOLOGY & THERAPY (2013)
Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo
Gloria Lutzny et al.
CANCER CELL (2013)
Targeting PKCε by miR-143 regulates cell apoptosis in lung cancer
Ni Zhang et al.
FEBS LETTERS (2013)
Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia
Julhash U. Kazi et al.
MEDICAL ONCOLOGY (2013)
miR-203 Inhibits Cell Proliferation and Migration of Lung Cancer Cells by Targeting PKCα
Chen Wang et al.
PLOS ONE (2013)
The Proto-oncogene PKCι Regulates the Alternative Splicing of Bcl-x Pre-mRNA
Jacqueline C. Shultz et al.
MOLECULAR CANCER RESEARCH (2012)
Protein kinase C, an elusive therapeutic target?
Daria Mochly-Rosen et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Proteins kinase Cε is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes
M. C. Caino et al.
ONCOGENE (2012)
A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer
Johan Vansteenkiste et al.
ONCOLOGY (2012)
Non-Small Cell Lung Carcinoma Cell Motility, Rac Activation and Metastatic Dissemination Are Mediated by Protein Kinase C Epsilon
M. Cecilia Caino et al.
PLOS ONE (2012)
Protein Kinase C δ Is a Downstream Effector of Oncogenic K-ras in Lung Tumors
Jennifer M. Symonds et al.
CANCER RESEARCH (2011)
Lung Cancer: Epidemiology, Etiology, and Prevention
Charles S. Dela Cruz et al.
CLINICS IN CHEST MEDICINE (2011)
Oncogenic Activity of Ect2 Is Regulated through Protein Kinase Cι-mediated Phosphorylation
Verline Justilien et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Protein kinase C epsilon as a cancer marker and target for anticancer therapy
Ewa Toton et al.
PHARMACOLOGICAL REPORTS (2011)
Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors
Toru Mukohara et al.
CANCER SCIENCE (2010)
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
Pedro Geraldes et al.
CIRCULATION RESEARCH (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase I Study of Enzastaurin Combined with Pemetrexed in Advanced Non-small Cell Lung Cancer
Chiharu Tanai et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Alberto Chiappori et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Recruitment of PKC-beta II to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70
C. Meyer Zum Bueschenfelde et al.
LEUKEMIA (2010)
Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction
Eiji Tahara et al.
CANCER BIOLOGY & THERAPY (2009)
Meta-analysis of Oncogenic Protein Kinase Cι Signaling in Lung Adenocarcinoma
Eda Erdogan et al.
CLINICAL CANCER RESEARCH (2009)
Down-regulation of PKCζ expression inhibits chemotaxis signal transduction in human lung cancer cells
Ying Liu et al.
LUNG CANCER (2009)
Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
C. Tekle et al.
BRITISH JOURNAL OF CANCER (2008)
Centrosomal PKCβII and pericentrin are critical for human prostate cancer growth and angiogenesis
Jeewon Kim et al.
CANCER RESEARCH (2008)
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
Yun Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Structural basis of protein kinase C isoform function
Susan F. Steinberg
PHYSIOLOGICAL REVIEWS (2008)
Protein kinase Cε is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner
Kyung-Mi Bae et al.
CANCER RESEARCH (2007)
Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiments
Axel-Rainer Hanauske et al.
INVESTIGATIONAL NEW DRUGS (2007)
Protein kinase Cι:: Human oncogene, prognostic marker and therapeutic target
Alan P. Fields et al.
PHARMACOLOGICAL RESEARCH (2007)
The role of protein kinase C activation and the vascular complications of diabetes
Net Das Evcimen et al.
PHARMACOLOGICAL RESEARCH (2007)
Mitogenic and drug-resistance mediating effects of PKCα require RLIP76
Sharad S. Singhal et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
Michael A. Carducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer
P Ritch et al.
LUNG CANCER (2006)
Determinants of differential doxorubicin sensitivity between SCLC and NSCLC
SS Singhal et al.
FEBS LETTERS (2006)
Protein kinase C (PKC) family in cancer progression
J Koivunen et al.
CANCER LETTERS (2006)
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-sinall-cell lung cancer
L Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Atypical protein kinase Cι, is an oncogene in human non-small cell lung cancer
RP Regala et al.
CANCER RESEARCH (2005)
Atypical protein kinase Cι plays a critical role in human lung cancer cell growth and tumorigenicity
RP Regala et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
JR Graff et al.
CANCER RESEARCH (2005)
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-α, in combination with cisplatin and genicitabine in patients with advanced non-small cell lung
MA Villalona-Calero et al.
CLINICAL CANCER RESEARCH (2004)
Down-regulation of protein kinase Cη by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel
E Sonnemann et al.
CANCER LETTERS (2004)
A p53-independent G1 cell cycle checkpoint induced by the suppression of protein kinase C α and θ isoforms
L Deeds et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
JD Winegarden et al.
LUNG CANCER (2003)
Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human breast cancer and ovarian cancer xenografts
BA Teicher et al.
INVESTIGATIONAL NEW DRUGS (2002)
Share Paper
